3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Phase 2
1
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
26
Lymphoma, Non-Hodgkin
18
Lymphoma
17
Lymphoma, Follicular
15
Lymphoma, Mantle-Cell
14
Lymphoma, B-Cell, Marginal Zone
12
Lymphoma, B-Cell
10
Lymphoma, Large B-Cell, Diffuse
9
Multiple Myeloma
8
Leukemia
6
Waldenstrom Macroglobulinemia
5
Hodgkin Disease
5
Neoplasms
4
Sezary Syndrome
3
Recurrence
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Neoplasm Metastasis
3
Mycosis Fungoides
3
Burkitt Lymphoma
3
Neoplasms, Plasma Cell
2
Lymphoma, T-Cell, Peripheral
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, T-Cell
2
Lymphatic Diseases
2
Leukemia, Myeloid, Acute
2
Leukemia, Hairy Cell
2
Immunoproliferative Disorders
2
Immune System Diseases
2
Brain Neoplasms
2
Advanced Solid Tumor
2
Interventions
Paclitaxel
80
Trastuzumab
76
Fulvestrant
55
Cyclophosphamide
49
Capecitabine
42
Lapatinib
40
pembrolizumab
39
Docetaxel
38
palbociclib
36
Carboplatin
33
Letrozole
28
olaparib
23
Doxorubicin
23
Gemcitabine
21
Taxes
20
Everolimus
20
ribociclib
19
abemaciclib
19
Ado-Trastuzumab Emtansine
18
pertuzumab
17
Radiotherapy
17
Magnetic Resonance Spectroscopy
17
Bevacizumab
16
130-nm albumin-bound paclitaxel
16
exemestane
15
Vinorelbine
15
Cisplatin
15
veliparib
14
Biopsy
14
Alpelisib
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Breast Neoplasms
×
Bendamustine Hydrochloride
×
Clear all
NCT00661739
2011-09-02
RiTa
GBG Forschungs GmbH
Phase 1
Completed
38 enrolled